Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLChristin Schütz, Andreas Burchert, Sabrina Inselmann et al.|Leukemia|2017Cited by 106
Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion GenesSebastian Kreil, Andreas Reiter, Lionel Adès et al.|Blood|2015Cited by 35
Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski TrialAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|Blood|2015Cited by 9
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKKS-E. Al-Batran, Nils Homann, Ekkehard Eigendorff et al.|Annals of Oncology|2019Cited by 8
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.Salah‐Eddin Al‐Batran, Nils Homann, Sylvie Lorenzen et al.|Journal of Clinical Oncology|2020Cited by 6